Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,200 | 5 | 84.8% |
| Grant | $1,000 | 1 | 6.9% |
| Food and Beverage | $917.82 | 10 | 6.4% |
| Travel and Lodging | $272.11 | 5 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | $13,228 | 18 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,000 | 1 | $0 (2017) |
| Roche Diagnostics Corporation | $87.21 | 1 | $0 (2019) |
| Ipsen Pharma SAS | $74.99 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,608 | 12 | Mirum Pharmaceuticals, Inc. ($8,533) |
| 2022 | $4,695 | 7 | Mirum Pharmaceuticals, Inc. ($4,695) |
| 2019 | $87.21 | 1 | Roche Diagnostics Corporation ($87.21) |
| 2017 | $1,000 | 1 | Merck Sharp & Dohme Corporation ($1,000) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Ipsen Pharma SAS | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $74.99 | General |
| Category: Rare Disease | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: Alagille syndrome | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $118.66 | General |
| Category: Alagille syndrome | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $116.46 | General |
| Category: Alagille syndrome | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $69.64 | General |
| Category: Alagille syndrome | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $40.43 | General |
| Category: Alagille syndrome | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $23.96 | General |
| Category: Alagille syndrome | ||||||
| 08/03/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $16.96 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $143.48 | General |
| Category: Alagille syndrome | ||||||
| 08/02/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $28.26 | General |
| Category: Alagille syndrome | ||||||
| 03/27/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| Category: Alagille syndrome | ||||||
| 12/26/2022 | Mirum Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 09/14/2022 | Mirum Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 09/14/2022 | Mirum Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $162.50 | General |
| 08/20/2022 | Mirum Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $124.91 | General |
| 08/20/2022 | Mirum Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $79.48 | General |
| 08/20/2022 | Mirum Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $66.98 | General |
| 08/20/2022 | Mirum Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $36.01 | General |
| 11/08/2019 | Roche Diagnostics Corporation | RS Harmony Test Related Products (Device) | Food and Beverage | In-kind items and services | $87.21 | General |
| Category: Sequencing | ||||||
| 01/11/2017 | Merck Sharp & Dohme Corporation | — | Grant | Cash or cash equivalent | $1,000.00 | General |
About Dr. Alyssa Kriegermeier, M.D
Dr. Alyssa Kriegermeier, M.D is a Pediatric Gastroenterology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2011. The National Provider Identifier (NPI) number assigned to this provider is 1285923078.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alyssa Kriegermeier, M.D has received a total of $14,390 in payments from pharmaceutical and medical device companies, with $8,608 received in 2024. These payments were reported across 21 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($12,200).
Practice Information
- Specialty Pediatric Gastroenterology
- Location Chicago, IL
- Active Since 04/01/2011
- Last Updated 05/18/2020
- Taxonomy Code 2080P0206X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1285923078
Products in Payments
- Livmarli (Drug) $8,533
- RS Harmony Test Related Products (Device) $87.21
- IQIRVO (Drug) $74.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Gastroenterology Doctors in Chicago
Dr. Joshua Wechsler, M.d, M.D
Pediatric Gastroenterology — Payments: $332,401
Valeria Cohran, M.d, M.D
Pediatric Gastroenterology — Payments: $136,667
Dr. Lee Bass, M.d, M.D
Pediatric Gastroenterology — Payments: $99,625
Stefano Guandalini, M.d,, M.D,
Pediatric Gastroenterology — Payments: $9,633
Ruba Azzam
Pediatric Gastroenterology — Payments: $8,754
Ritu Verma
Pediatric Gastroenterology — Payments: $8,422